Epigenetics in Cancer: A Hematological Perspective

Activation of proto-oncogenes by disruption of chromosome neighborhoods

(2016) D. Hnisz et al.   SCIENCE

IDH2 inhibition in AML: Finally progress?

(2015) Eytan M. Stein   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation

(2015) Claire Mazumdar et al.   Cell Stem Cell

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

(2015) M. Maio et al.   CLINICAL CANCER RESEARCH

Panobinostat for the Treatment of Multiple Myeloma

(2015) J. P. Laubach et al.   CLINICAL CANCER RESEARCH

Metabolism and epigenetics: a link cancer cells exploit

(2015) Alessandro Carrer et al.   CURRENT OPINION IN BIOTECHNOLOGY

Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond

(2015) Chun-Wei Chen et al.   EXPERIMENTAL HEMATOLOGY

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

(2015) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms

(2015) Jasper Mullenders et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Insulator dysfunction and oncogene activation in IDH mutant gliomas

(2015) William A. Flavahan et al.   NATURE

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors

(2015) Christine M. Fillmore et al.   NATURE

Epigenome editing made easy

(2015) Gabriel E Zentner et al.   NATURE BIOTECHNOLOGY

Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression

(2015) J Y Kang et al.   ONCOGENE

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions

(2015) Tae Kon Kim et al.   SEMINARS IN HEMATOLOGY

Epigenetics Meets Immune Checkpoints

(2015) Alessia Covre et al.   SEMINARS IN ONCOLOGY

Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models

(2015) A Covre et al.   OncoImmunology

AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes

(2014) Aniruddha J. Deshpande et al.   CANCER CELL

The role of mutations in epigenetic regulators in myeloid malignancies

(2014) Brittany A. Woods et al.   IMMUNOLOGICAL REVIEWS

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies

(2014) K. L. Rice et al.   JOURNAL OF INTERNAL MEDICINE

Selective Inhibitors of Protein Methyltransferases

(2014) H. Ümit Kaniskan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts

(2014) Pragya Srivastava et al.   LEUKEMIA RESEARCH

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

Epigenetic drugs as immunomodulators for combination therapies in solid tumors

(2014) Luca Sigalotti et al.   PHARMACOLOGY & THERAPEUTICS

Epigenetics reloaded: the single-cell revolution

(2014) Poonam Bheda et al.   TRENDS IN CELL BIOLOGY

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

(2013) J. D. Wolchok et al.   ANNALS OF ONCOLOGY

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

(2013) S. R. Daigle et al.   BLOOD

Targeting IDH: the next big thing in AML

(2013) M. Levis   BLOOD

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia

(2013) O. Abdel-Wahab et al.   BLOOD

Influence of Metabolism on Epigenetics and Disease

(2013) William G. Kaelin et al.   CELL

Interplay between the Cancer Genome and Epigenome

(2013) Hui Shen et al.   CELL

Genome-Wide Epigenetics

(2013) Brian C. Capell et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

EZH2 in normal and malignant hematopoiesis

(2013) K Lund et al.   LEUKEMIA

Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms

(2013) Ayana Kon et al.   NATURE GENETICS

A panoramic view of acute myeloid leukemia

(2013) Sai-Juan Chen et al.   NATURE GENETICS

CRISPRs and epigenome editing

(2013) Nicole Rusk   NATURE METHODS

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

(2013) F. Wang et al.   SCIENCE

Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities

(2013) R. A. Cairns et al.   Cancer Discovery

Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions

(2012) A. E. Teschendorff et al.   BIOINFORMATICS

Mutant DNMT3A: teaming up to transform

(2012) C. Thiede   BLOOD

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

(2012) F. Damm et al.   BLOOD

ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression

(2012) Omar Abdel-Wahab et al.   CANCER CELL

Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide

(2012) Sandra Coral et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The HARE-HTH and associated domains

(2012) L. Aravind et al.   CELL CYCLE

TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group

(2012) Verena I. Gaidzik et al.   JOURNAL OF CLINICAL ONCOLOGY

The ASXL–BAP1 axis: new factors in myelopoiesis, cancer and epigenetics

(2012) O Abdel-Wahab et al.   LEUKEMIA

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

(2012) Masato Sasaki et al.   NATURE

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Epigenetic Readers in Cancer

(2012) Mark A. Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

(2012) Li Shen et al.   PLoS One

Gatekeepers of chromatin: Small metabolites elicit big changes in gene expression

(2012) Salma Kaochar et al.   TRENDS IN BIOCHEMICAL SCIENCES

The role of histone methyltransferase EZH2 in myelodysplastic syndromes

(2012) Feng Xu et al.   Expert Review of Hematology

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

(2011) C. L. Green et al.   BLOOD

Peripheral T-cell lymphoma

(2011) F. M. Foss et al.   BLOOD

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

(2011) K. H. Metzeler et al.   BLOOD

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

(2011) W.-C. Chou et al.   BLOOD

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status

(2011) J Šímová et al.   BRITISH JOURNAL OF CANCER

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

(2011) Scott R. Daigle et al.   CANCER CELL

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L

(2011) Kathrin M. Bernt et al.   CANCER CELL

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Epigenetics in Alternative Pre-mRNA Splicing

(2011) Reini F. Luco et al.   CELL

Identification of 67 Histone Marks and Histone Lysine Crotonylation as a New Type of Histone Modification

(2011) Minjia Tan et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

How epigenetics can explain human metastasis: A new role for microRNAs

(2011) Amaia Lujambio et al.   CELL CYCLE

A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction

(2011) Winston Timp et al.   CELL CYCLE

Regulation of chromatin by histone modifications

(2011) Andrew J Bannister et al.   CELL RESEARCH

Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes

(2011) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

(2011) M J Walter et al.   LEUKEMIA

Acetyl-CoA Induces Cell Growth and Proliferation by Promoting the Acetylation of Histones at Growth Genes

(2011) Ling Cai et al.   MOLECULAR CELL

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

Dnmt3a is essential for hematopoietic stem cell differentiation

(2011) Grant A Challen et al.   NATURE GENETICS

Cancer epigenetics reaches mainstream oncology

(2011) Manuel Rodríguez-Paredes et al.   NATURE MEDICINE

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas

(2011) Russell J. H. Ryan et al.   PLoS One

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

(2011) A. J. Christiansen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1

(2010) S. Lugthart et al.   BLOOD

A Higher-Order Complex Containing AF4 and ENL Family Proteins with P-TEFb Facilitates Oncogenic and Physiologic MLL-Dependent Transcription

(2010) Akihiko Yokoyama et al.   CANCER CELL

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

(2010) Maria E. Figueroa et al.   CANCER CELL

Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia

(2010) I. H. I. M. Hollink et al.   HAEMATOLOGICA

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

AFF4, a Component of the ELL/P-TEFb Elongation Complex and a Shared Subunit of MLL Chimeras, Can Link Transcription Elongation to Leukemia

(2010) Chengqi Lin et al.   MOLECULAR CELL

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

(2010) Ryan D Morin et al.   NATURE GENETICS

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of Alternative Splicing by Histone Modifications

(2010) R. F. Luco et al.   SCIENCE

Genome-Wide Views of Chromatin Structure

(2009) Oliver J. Rando et al.   Annual Review of Biochemistry

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

(2009) O. Abdel-Wahab et al.   BLOOD

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features

(2009) M. E. Figueroa et al.   BLOOD

Isoform-specific histone deacetylase inhibitors: The next step?

(2009) Sriram Balasubramanian et al.   CANCER LETTERS

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

(2009) A Tefferi et al.   LEUKEMIA

Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts

(2009) Akiko Doi et al.   NATURE GENETICS

Differential chromatin marking of introns and expressed exons by H3K36me3

(2009) Paulina Kolasinska-Zwierz et al.   NATURE GENETICS

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia

(2009) Dorothee Mueller et al.   PLOS BIOLOGY

H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias

(2008) Andrei V. Krivtsov et al.   CANCER CELL

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE